<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thomas M van Himbergen</style></author><author><style face="normal" font="default" size="100%">Nirupa R Matthan</style></author><author><style face="normal" font="default" size="100%">Nancy A Resteghini</style></author><author><style face="normal" font="default" size="100%">Seiko Otokozawa</style></author><author><style face="normal" font="default" size="100%">Masumi Ai</style></author><author><style face="normal" font="default" size="100%">Evan A Stein</style></author><author><style face="normal" font="default" size="100%">Peter H Jones</style></author><author><style face="normal" font="default" size="100%">Schaefer, Ernst J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Lipid Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Absorption</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Markers</style></keyword><keyword><style  face="normal" font="default" size="100%">Cholesterol</style></keyword><keyword><style  face="normal" font="default" size="100%">Diabetes Complications</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluorobenzenes</style></keyword><keyword><style  face="normal" font="default" size="100%">Heptanoic Acids</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperlipidemias</style></keyword><keyword><style  face="normal" font="default" size="100%">lipids</style></keyword><keyword><style  face="normal" font="default" size="100%">Lipoproteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Phytosterols</style></keyword><keyword><style  face="normal" font="default" size="100%">Pyrimidines</style></keyword><keyword><style  face="normal" font="default" size="100%">Pyrroles</style></keyword><keyword><style  face="normal" font="default" size="100%">Serum Albumin</style></keyword><keyword><style  face="normal" font="default" size="100%">Sterols</style></keyword><keyword><style  face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style  face="normal" font="default" size="100%">{Hydroxymethylglutaryl-CoA} Reductase Inhibitors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/19043140</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">50</style></volume><pages><style face="normal" font="default" size="100%">730–739</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">We measured plasma markers of cholesterol synthesis (lathosterol) and absorption (campesterol, sitosterol, and cholestanol) in order to compare the effects of maximal doses of rosuvastatin with atorvastatin and investigate the basis for the significant individual variation in lipid lowering response to statin therapy. Measurements were performed in participants (n = 135) at baseline and after 6 weeks on either rosuvastatin (40 mg/day) or atorvastatin (80 mg/day) therapy. Plasma sterols were measured using gas-liquid chromatography. Rosuvastatin and atorvastatin significantly {(P} {\textless} 0.001) altered plasma total cholesterol {(C)} levels by -40%, and the ratios of {lathosterol/C} by -64% and -68%, and {campesterol/C} by +52% and +72%, respectively, with significant differences {(P} {\textless} 0.001) between the treatment groups for the latter parameter. When using absolute values of these markers, subjects with the greatest reductions in both synthesis (lathosterol) and absorption (campesterol) had significantly greater reductions in total C than subjects in whom the converse was true (-46% versus -34%</style></abstract><notes><style face="normal" font="default" size="100%">{PMID:} 19043140</style></notes></record></records></xml>